In addition to the substantial clinical burden that is tied to diabetes in US, the annual economic burden that is associated with disease management jumps from $18 billion to $232 billion between the transition of pre-diabetes to full-fledged diabetes. In an effort to prevent that shift to diabetes, mitigate the development of detrimental comorbidities, and to avoid downstream consequences such as end-stage organ damage, the panelists acknowledged that it is critical to diagnose and treat patients earlier and more aggressively. Although patients will present with varying stages of disease upon initial diagnosis, there is optimism that opportunities can be created and seized to better patient outcomes, improve quality of life, and reduce the managed care burden.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More